Exosome Diagnostics boosts research and management team
This article was originally published in Clinica
Executive Summary
Exosome Diagnostics (New York, New York), a company focused on commercialising its proprietary genetics-based diagnostics for oncology and endocrinology, has appointed Johan Skog as director of genetics research; Wayne Comper as chief scientific officer; and Tom Tsakeris as director of regulatory affairs. Mr Skog discovered and invented Exosome’s blood-based diagnostics and in his new role will oversee the firm’s research programme. He will continue as a post-doctoral researcher at the molecular neurogenetics unit of Massachusetts General Hospital. Mr Comper joins from AusAm Biotechnologies; he has had more than 160 articles published in peer reviewed international journals. Mr Tsakeris joins from Devices and Diagnostics Consulting Group, where he was president. He has held management roles at the US FDA, including at the Office for Device Evaluation (director) and the Center for Devices and Radiological Health.
You may also be interested in...
Asia Regulatory Forum Update
Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.
Saudi Arabia adopts interim device authorisation regulation
Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.
Canada takes action to increase more adverse event reporting
The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.